Prime Medicine, Inc.
PRME- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001894562
No open-market purchases or sales by Prime Medicine, Inc. insiders were filed in the last 90 days; 187 institutions reported holding it in 13F filings for Q2 2026, worth $393.5M in total; ARK Invest is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Prime Medicine, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 66 | 1 | 76 | +11 |
| Shares | 41.3M | 3.90K | 41.7M | +420.4K (+1.0%) |
| Value | $767.8M | $72.0K | $512.1M | −$255.6M (−33.3%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Prime Medicine, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Greenwich Wealth Management LLC | 349,000 | $4.29M | 0.47% |
| Wexford Capital LP | 153,705 | $1.89M | 0.39% |
| Swiss National Bank | 41,900 | $515.4K | 0.00% |
| Jump Financial, LLC | 32,500 | $399.8K | 0.02% |
| Panagora Asset Management Inc | 32,197 | $396.0K | 0.00% |
| State of Wisconsin Investment Board | 17,999 | $221.4K | 0.00% |
| Red Lighthouse Investment Management, LLC | 14,950 | $183.9K | 0.09% |
| Capstone Investment Advisors, LLC | 14,551 | $179.0K | 0.01% |
| Janus Henderson Group PLC | 14,091 | $173.1K | 0.00% |
| Millennium Management LLC | 10,759 | $132.0K | 0.00% |
| Wells Fargo & Company | 1,936 | $23.8K | 0.00% |
| Lazard Asset Management LLC | 1,547 | $18.0K | 0.00% |
| Allspring Global Investments Holdings, LLC | 1,151 | $14.2K | 0.00% |
| TCI Wealth Advisors, Inc. | 231 | $2.84K | 0.00% |
| Federated Hermes, Inc. | 45 | $554 | 0.00% |
| Endurance Wealth Management, Inc. | 500 | $0 | 0.00% |
| CWM, LLC | 15 | $0 | 0.00% |
| Covestor Ltd | 9 | $0 | 0.00% |
Sold out (7)
Institutions that held Prime Medicine, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Caas Capital Management LP | 89,331 | $1.66M |
| Ghisallo Capital Management LLC | 70,000 | $1.30M |
| Point72 Middle East FZE | 37,609 | $698.8K |
| Walleye Capital LLC | 30,000 | $557.4K |
| LMR Partners LLP | 17,760 | $330.0K |
| Levin Capital Strategies, L.P. | 10,585 | $196.7K |
| Leonteq Securities AG | 200 | $3.72K |
Not filed for Q1 2023 yet (1)
Institutions that held Prime Medicine, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Alpha Paradigm Partners, LLC | 3,895 | $72.0K |